Service Gastroentérologie, CHU St Etienne
Indication of infliximab is very important in first line of therapy on Crohn’s disease. We must know predictive factors of disabling evolution in CD and predictive factors of these news strategies. We report these studies an analyse their impacts in clinical practice. Healing mucosa must be a new end point of our strategy.